DiscGenics has announced that it has received the go-ahead from an independent data safety monitoring committee (DSMC) to enrol the final 24 patients in its first-in-human US clinical study of IDCT, an allogeneic, injectable disc cell therapy for mild to moderate degenerative disc disease (DDD).
The DSMC completed a third and final planned mid-trial safety review following treatment of the first six subjects in the high dose study cohort, each of whom was treated based on random assignment into one of three arms: high dose IDCT study treatment, vehicle or placebo. The DSMC reported there were no safety issues and recommended that the study proceed with completion of patient enrolment with no changes to the protocol.
“We are delighted to commence the final enrolment stage in our U.S. study of IDCT for DDD and are thrilled that the first 36 patients have now been safely treated,” said Flagg Flanagan, chief executive officer and chairman of the board of directors for DiscGenics. “This is a blinded, first-in-human study where neither the treating clinicians nor the patients know what treatment is being administered. As a result, performance of periodic safety checks by an unblinded and independent body was essential to ensuring the ongoing safety of IDCT in a clinical setting. The members of the DSMC played a critical role in this process and we would like to sincerely thank them for their time and thoughtful review of the blinded safety data.”
The IDCT trial is a prospective, randomised, double-blinded, vehicle-and placebo-controlled, multicentre clinical study to evaluate the safety and preliminary efficacy of IDCT in subjects with single-level, symptomatic lumbar intervertebral disc degeneration. The trial is underway in 14 centres across 12 states in the USA and will enroll 60 subjects.
Those subjects who meet all eligibility criteria are being randomised to one of four treatment cohorts: low dose IDCT (n=20), high dose IDCT (n=20), vehicle (n=10) and placebo (n=10). Each subject receives a single intradiscal injection of his or her assigned treatment into the target symptomatic lumbar intervertebral disc. Following treatment, subjects will be observed and evaluated for a period of one year, with a one-year extension period. Primary outcome measures include safety and reduction in pain. Secondary outcome measures include reduction in disability and radiographic improvement.
IDCT is also being evaluated in a multicentre safety study in Japan, which is supported by a Clinical Trial Notification (CTN) approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).